BioNTech and Pfizer plan to fabricate a further 500m doses of their Covid-19 vaccine this 12 months, bringing their whole manufacturing goal for 2021 to 2.5bn pictures.
The German biotech group mentioned in its annual earnings report on Tuesday that elevated output was doable due to optimised manufacturing processes and an enlargement of its manufacturing and provide community for the vaccine, often called BNT162b2, or Comirnaty.
The businesses had initially pledged to supply 1.3bn doses of the breakthrough shot in 2021 earlier than growing the goal to 2bn doses in January.
“Further measures and discussions with potential companions to additional increase the manufacturing capability and community are ongoing,” BioNTech mentioned. “We and our collaboration companions have equipped greater than 200m doses of our Covid-19 vaccine worldwide, as of March 23 2021.”
In whole, BioNTech and Pfizer have signed orders for 1.4bn doses for supply this 12 months, representing estimated revenues for BioNTech of roughly €9.8bn from its share of the gross sales.
The businesses count on to signal additional provide contracts in the end, BioNTech mentioned.
The European Medicines Company on Friday permitted BioNTech’s Marburg plant in Germany to supply the vaccine. The corporate acquired the positioning in October and goals to supply 1bn vaccines there by the top of the 12 months.
